Skip to main navigation
Aimmune
  • Contact
Menu CLOSE X
CLOSE X
  • About Us
    • Company Overview
    • History
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
    • Contact
  • Therapeutic Focus
    • Food Allergies
    • CODIT™ & Oral Immunotherapy
    • Helpful Resources
  • Pipeline
    • Development Pipeline
    • AR101 for Peanut Allergy
    • Discovery Program
    • Expanded Access Policy
  • News & Events
    • Press Releases
    • Medical Congresses
    • Media Resources
  • Investor Relations
    • Investor Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Financials & Filings
      • Annual Reports
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Investor FAQs
  • Contact

Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy

  • Read more about Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy

Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference

  • Read more about Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference

Aimmune Therapeutics Reports Second Quarter 2015 Financial Results

  • Read more about Aimmune Therapeutics Reports Second Quarter 2015 Financial Results

Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  • Read more about Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Aimmune Therapeutics Announces Pricing of Initial Public Offering

  • Read more about Aimmune Therapeutics Announces Pricing of Initial Public Offering

Allergen Research Corporation Announces $17 Million Series A Financing

  • Read more about Allergen Research Corporation Announces $17 Million Series A Financing

Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101

  • Read more about Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101

Aimmune Therapeutics Announces Positive Phase 2 Study Results of AR101 for the Treatment of Peanut Allergy

  • Read more about Aimmune Therapeutics Announces Positive Phase 2 Study Results of AR101 for the Treatment of Peanut Allergy

Aimmune Therapeutics to Announce Phase 2 Data at EAACI Congress 2015 for Study of Peanut Allergy Desensitization Treatment

  • Read more about Aimmune Therapeutics to Announce Phase 2 Data at EAACI Congress 2015 for Study of Peanut Allergy Desensitization Treatment

Allergen Research Corporation Renamed Aimmune Therapeutics

  • Read more about Allergen Research Corporation Renamed Aimmune Therapeutics

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Current page 9
  • Page 10
  • Page 11
  • Page 12
  • Next page Next ›
  • Last page Last »
Subscribe to

Shareholder Tools

  • Print Page
  • Email Alerts
  • IR Contact
  • RSS Feeds
About Us
  • Company Overview
  • History
  • Leadership
  • Board of Directors
  • Scientific Advisory Board
  • Partners
  • Careers
  • Contact
Therapeutic Focus
  • Food Allergies
  • CODIT™ & Oral Immunotherapy
  • Helpful Resources
Pipeline
  • Development Pipeline
  • AR101 for Peanut Allergy
  • Discovery Program
  • Expanded Access Policy
News & Events
  • Press Releases
  • Medical Congresses
  • Media Resources
Investor Relations
  • Investor Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Financials & Filings
  • Corporate Governance
  • Stock Information
  • Investor FAQs
© 2018 Aimmune Therapeutics.
  • All rights reserved.
  • Terms of Use
  • Twitter Guidelines

Aimmune’s food allergy treatments are investigational and are not FDA-approved.

ShareThis Copy and Paste
Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...